Ascendia

  MARKET NEWS

IMUNON & Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination With Avastin in Advanced Ovarian Cancer
Nexcella Announces Patients Already Treated With CAR-T NXC-201; Estimates 100-Patient Total Enrollment for FDA Approval BLA Submission
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. & Portfolio of Investigational Therapeutics
Redx & Jounce Announce Recommended Business Combination
VBL Therapeutics & Notable Labs Announce Definitive Merger Agreement
BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer

  FEATURED EDITORIAL

  COMPANY PROFILE

Micropore Technologies is a global process technology and service provider to the pharmaceutical industry featuring patented crossflow technology for the commercially scalable development of topical and sterile injectable drug products. Originally spun-out of Loughborough University’s internationally renowned chemical engineering department, the company’s global headquarters and technical center are located at Wilton Center, UK with offices and operations in the USA, India, South Korea & Japan supporting over a hundred clients and strategic partners. Micropore’s technology enables scalable formulation of mono-disperse microspheres, nanoparticles and emulsions. Our array of mixing devices are constructed to operate from early stage high throughput screening on the benchtop to fully integrated GMP manufacturing SKIDs. We offer best in class formulation consultation, in house discovery through preclinical feasibility trials, and process engineering services to supporting the development of commercial manufacturing processes. Click here for more.

  EXCLUSIVE ONLINE CONTENT

EyePoint & Rallybio Announce Research Collaboration

EyePoint & Rallybio Announce Research Collaboration

Rallybio Corporation and EyePoint Pharmaceuticals, Inc recently announced a research collaboration. The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component….

PDS Biotech Completes Successful Meeting With FDA for Triple Combination of PDS0101, PDS0301 & a Commercial Immune Checkpoint Inhibitor

PDS Biotech Completes Successful Meeting With FDA for Triple Combination of PDS0101, PDS0301 & a Commercial Immune Checkpoint Inhibitor

Received guidance on registrational path for combination in recurrent/metastatic, immune checkpoint inhibitor refractory head and neck cancer….

Ocean Biomedical Celebrates Discovery of Bispecific Antibodies & Immune Checkpoint Inhibitors That Kill Glioblastoma Cells & Melanoma Cells & Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%

Ocean Biomedical Celebrates Discovery of Bispecific Antibodies & Immune Checkpoint Inhibitors That Kill Glioblastoma Cells & Melanoma Cells & Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%

Ocean Biomedical, Inc. celebrates the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant….

Cue Biopharma Enters Strategic Collaboration & Option Agreement With Ono Pharmaceutical 

Cue Biopharma Enters Strategic Collaboration & Option Agreement With Ono Pharmaceutical 

Cue Biopharma, Inc. recently announced a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. for CUE-401, a bispecific protein designed to induce and expand regulatory….

Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase

Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase

Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, recently announced the development of a new enzyme for double strand oligonucleotide formation with high….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

Abstract: A team of bioavailability experts at Catalent used the in-house bioavailability enhancement platform, OptiForm® Solution Suite, to optimize and develop Phase 1 clinical formulation within a short timeline. Catalent’s global supply chain expertise was utilized for packaging and distributing …

WHITEPAPER WORKSHOP - Soft Mist Inhalers

WHITEPAPER WORKSHOP - Soft Mist Inhalers

Soft mist inhalers (SMIs) are a versatile technology suitable for the delivery of both small and complex large molecules, optimising lung deposition whilst minimising oropharyngeal deposition.

The Resyca® SMI is a joint venture between Recipharm and Medspray that harnesses …

WHITEPAPER - Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development

WHITEPAPER - Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development

Manufacturing Phase 1 clinical material in as little as 12–16 months

Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more molecules in development fall under …

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

Abstract: Catalent’s proprietary Zydis® ODT platform is backed by a large number of clinical studies. This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets. Factors addressed include bioavailability, safety, side effects, speed/pharmacokinetics, variability, …

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

 

Synchronizing and controlling API delivery, Extrusion-Spheronization (E-S) offers pharmaceutical drug developers a robust technique to develop and manufacture today’s most complex oral sold dose therapeutics.

Manufacturing oral solid dose API’s into spheres via Extrusion-Spheronization is not new. What is …

WHITEPAPER - Antibody-Based Drug Discovery at the Speed of Light

WHITEPAPER - Antibody-Based Drug Discovery at the Speed of Light

Capabilities and technology combine to provide First-to-Human antibody discovery, development and clinical manufacturing. Speed, scientific expertise and efficiency can surmount the high attrition rates of early antibody discovery and achieve first-to-market delivery of new therapeutics.

Download our whitepaper and learn …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 8 – Parenteral Contract Manufacturing
March 15 – Polymers & Biomaterials